Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02518698 · ClinicalTrials.gov registry record
Treatment Patterns in Castrate Resistant Prostate Cancer Patients With Bone Metastases in a Medicare Population
A clinical trial, sponsored by Bayer.
- Completed
- Registry status
- 1,163
- Enrollment target
NCT02518698 is a clinical trial that has completed, run by Bayer. The registered enrollment target is 1,163 participants.
The verdict
NCT02518698 has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 1,163 participants
- Enrollment target
Study Summary
The goal of the study is to provide a detailed description of treatments for CRPC (Castrate Resistant Prostate Cancer) patients with bone metastases and the resource utilization and costs associated with that diagnosis and subsequent treatments.
Interventions
- DRUG Radium-223 dichloride (Xofigo, BAY88-8223)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,163 participants |
| Start Date | 2015-08-31 |
| Est. Completion | 2017-09-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02518698
The ClinicalTrials.gov registry entry for NCT02518698 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,163 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Radium-223 dichloride (Xofigo, BAY88-8223) is the first listed.
NCT02518698 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02518698 about?
NCT02518698 is a clinical study titled "Treatment Patterns in Castrate Resistant Prostate Cancer Patients With Bone Metastases in a Medicare Population". The goal of the study is to provide a detailed description of treatments for CRPC (Castrate Resistant Prostate Cancer) patients with bone metastases and the resource utilization and costs associated with that diagnosis and subsequent treatments.
What is the current status of trial NCT02518698?
This trial is currently completed. The enrollment target is 1,163 participants. The study started on 2015-08-31. Estimated completion is 2017-09-30.
What interventions are being tested in trial NCT02518698?
The interventions under investigation include: Radium-223 dichloride (Xofigo, BAY88-8223) (DRUG).
Who is sponsoring clinical trial NCT02518698?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.